{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T17:08:45Z","timestamp":1780852125319,"version":"3.54.1"},"reference-count":21,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.3892\/br.2016.682","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T18:51:40Z","timestamp":1463683900000},"page":"41-44","source":"Crossref","is-referenced-by-count":78,"title":["The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer"],"prefix":"10.3892","volume":"5","author":[{"given":"SU","family":"WEI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUI","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BEI","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,5,19]]},"reference":[{"key":"key20180107141440_b1-br-0-0-682","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00006254-198406000-00001","article-title":"Detection of malignant ovarian neoplasms: A review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection","volume":"39","author":"Smith","year":"1984","journal-title":"Obstet Gynecol Surv"},{"key":"key20180107141440_b2-br-0-0-682","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/0008-5472.CAN-04-0746","article-title":"Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"key20180107141440_b3-br-0-0-682","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0020-7292(06)60032-5","article-title":"Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"key20180107141440_b4-br-0-0-682","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1447-0756.2008.00869.x","article-title":"Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index","volume":"35","author":"Enakpene","year":"2009","journal-title":"J Obstet Gynaecol Res"},{"key":"key20180107141440_b5-br-0-0-682","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass","volume":"127","author":"Karlsen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"key20180107141440_b6-br-0-0-682","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/gyno.1995.1121","article-title":"Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure","volume":"57","author":"Folk","year":"1995","journal-title":"Gynecol Oncol"},{"key":"key20180107141440_b7-br-0-0-682","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0889-8588(03)00063-7","article-title":"Ovarian cancer screening","volume":"17","author":"Urban","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20180107141440_b8-br-0-0-682","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: A review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod"},{"key":"key20180107141440_b9-br-0-0-682","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"key20180107141440_b10-br-0-0-682","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Levanon","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107141440_b11-br-0-0-682","doi-asserted-by":"crossref","first-page":"358.e1","DOI":"10.1016\/j.ajog.2011.05.017","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"Holcomb","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"key20180107141440_b12-br-0-0-682","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-1596-8-11","article-title":"Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response","volume":"8","author":"Hamed","year":"2013","journal-title":"Diagn Pathol"},{"key":"key20180107141440_b13-br-0-0-682","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0b013e318234f852","article-title":"The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis","volume":"22","author":"Kadija","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"key20180107141440_b14-br-0-0-682","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2012.11.026","article-title":"Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome","volume":"128","author":"Sandri","year":"2013","journal-title":"Gynecol Oncol"},{"key":"key20180107141440_b15-br-0-0-682","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"key20180107141440_b16-br-0-0-682","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.26129","article-title":"Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer","volume":"130","author":"Park","year":"2012","journal-title":"Int J Cancer"},{"key":"key20180107141440_b17-br-0-0-682","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key20180107141440_b18-br-0-0-682","doi-asserted-by":"crossref","first-page":"8271","DOI":"10.3390\/ijms14048271","article-title":"Ovarian cancer: Can proteomics give new insights for therapy and diagnosis?","volume":"14","author":"Toss","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"key20180107141440_b19-br-0-0-682","first-page":"517","article-title":"Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality","volume":"71","author":"Yancik","year":"1993","journal-title":"Cancer"},{"key":"key20180107141440_b20-br-0-0-682","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","article-title":"HE4 a novel tumour marker for ovarian cancer: Comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases","volume":"32","author":"Molina","year":"2011","journal-title":"Tumour Biol"},{"key":"key20180107141440_b21-br-0-0-682","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1055-9965.EPI-08-0150","article-title":"Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer","volume":"17","author":"Lowe","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Biomedical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/br.2016.682\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T14:22:02Z","timestamp":1515334922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/br.2016.682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,19]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,19]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.3892\/br.2016.682"],"URL":"https:\/\/doi.org\/10.3892\/br.2016.682","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,19]]}}}